ProCE Banner Activity

Phase II Trial of Cladribine + LDAC + Venetoclax Alternating With Azacitidine + Venetoclax in Patients With Newly Diagnosed AML

Conference Coverage
Slideset

In this phase II study, patients with newly diagnosed acute myeloid leukemia who were older or unfit for intensive chemotherapy achieved an MRD-negativity rate of 76% and a composite complete response rate of 86% with CLAD-LDAC-VEN alternating with AZA-VEN.

Released: December 13, 2024

Expiration: December 12, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation